BIERAU SCHMEISER KATJA

Their core work

PILOTALITY is a specialist consultancy or expert firm operating in pharmaceutical sciences, with deep knowledge of antibody-drug conjugates (ADCs), bioconjugation chemistry, and drug safety testing. In EU consortia they function as a subject-matter expert, bringing applied expertise to coordination and support projects rather than conducting primary laboratory research. Their participation in ACORN placed them in the therapeutic nanoparticle space alongside carbon monoxide-releasing molecules, while their Biosafety project work focused on complement-activation pathology — a critical but niche safety concern during drug development. The company's name and profile suggest a lean, expert-led structure built around one or two specialist practitioners contributing targeted scientific knowledge to international consortia.

What they specialise in

How they've shifted over time

In its first H2020 project (2018), PILOTALITY contributed to the molecular engineering end of drug development — ADC design and bioconjugation, where chemistry meets biology to build targeted cancer therapeutics. By 2020, the focus had shifted clearly toward the safety and validation side: complement assays, in vitro biosafety testing, and clinical-pathway readiness. This is a logical professional trajectory — from building novel drug constructs to ensuring those constructs are safe enough to enter trials. The shift may reflect growing market demand for biosafety expertise as the ADC field matured and regulators tightened complement-activation requirements.

PILOTALITY appears to be moving toward the regulatory and clinical-validation end of the drug development pipeline, which suggests future relevance for consortia working on biologic drug safety, complement pathway assays, or preclinical-to-clinical translation.

How they like to work

PILOTALITY has participated exclusively as a consortium partner — never as coordinator — across both projects, signalling a preference for specialist contributor roles rather than project management. Both projects are CSA (Coordination and Support Actions), which typically involve expert advisory input, networking, and knowledge-sharing rather than original research execution. With 8 consortium partners across 6 countries in just 2 projects, their network breadth relative to project count is above average, suggesting they connect well across European institutions despite a lean project portfolio.

PILOTALITY has worked with 8 distinct consortium partners spread across 6 countries in only 2 projects, which is a relatively broad reach for such a small portfolio. No dominant geographic cluster is visible from the data, suggesting genuinely pan-European connections.

What sets them apart

PILOTALITY occupies a rare intersection: ADC/bioconjugation chemistry expertise combined with drug biosafety assay knowledge, covering both the construction and the safety validation of a biologic drug. Few organisations hold expertise across both the molecular engineering and the regulatory-safety dimensions of the same drug class. For a consortium building a project around novel biologics, ADC therapeutics, or complement-related drug safety, this organisation offers a specialist profile that is hard to replicate with generalist biotech firms.

Highlights from their portfolio

• Biosafety
  The higher-funded project (EUR 100,000) addresses complement-activation pathology — a niche but commercially critical safety bottleneck that affects nearly all biologic and nanomedicine drugs entering clinical trials.
• ACORN
  Combines two advanced drug-delivery approaches — carbon monoxide-releasing molecules and nanoparticle therapeutics — making it an unusually broad entry point into nanomedicine for a small private firm.